AbbVie Inc. (NYSE:ABBV) Receives $248.11 Average Target Price from Analysts

AbbVie Inc. (NYSE:ABBV) has received a consensus recommendation of “Moderate Buy” from the twenty-three analysts that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $248.1053.

ABBV has been the subject of a number of analyst reports. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a report on Tuesday, November 4th. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Bank of America boosted their target price on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Guggenheim boosted their price target on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the 2nd quarter worth about $26,000. Chelsea Counsel Co. purchased a new position in shares of AbbVie in the 3rd quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $28,000. Westend Capital Management LLC bought a new position in shares of AbbVie during the 4th quarter valued at approximately $29,000. Finally, Texas Capital Bancshares Inc TX purchased a new stake in AbbVie during the 3rd quarter valued at $31,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.5%

AbbVie stock opened at $219.21 on Thursday. AbbVie has a 1-year low of $164.39 and a 1-year high of $244.81. The firm has a 50 day simple moving average of $225.60 and a 200 day simple moving average of $217.41. The firm has a market capitalization of $387.42 billion, a price-to-earnings ratio of 166.07, a P/E/G ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts forecast that AbbVie will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.